MAJOR $CYDY ARTICLE - $9.00 Price Target So metas
Post# of 148168
Tweet this link (Cut and Paste)
Drug makers Merck, Johnson & Johnson, and GlaxoSmithKline dismantle Gilead in HIV drug race https://born2invest.com/articles/drug-makers-...UE.twitter
So how many people read this?
If we look at the figures, CytoDyn’s value proposition becomes a little clearer. If we look at a stock like Immunomedics, Inc. (IMMU) with a $4.5 billion market cap and a total available patient population of 22 thousand, then we can estimate that CytoDyn, with a patient population of around 170 thousand, could justify a valuation of around $9.00."